OBJECTIVES/HYPOTHESIS: To estimate the distribution of head and neck squamous cell carcinoma (HNSCC) recurrence after definitive chemoradiation therapy (CRT) among patients who underwent 18F-fluorodeoxyglucose positron-emission tomography and computed tomography (PET/CT) surveillance. STUDY DESIGN: Retrospective review. METHODS: HNSCC patients who underwent definitive CRT from 2001 to 2008 were evaluated for recurrence with serial PET/CT. Patients were excluded if they were previously treated for recurrent disease, were treated with surgery as the primary therapeutic modality, or had inadequate clinical follow-up. Recurrence was defined by histopathologic evidence of tumor. RESULTS: Three hundred eighty-eight patients were studied. Patients in whom recurrence was not detected were followed clinically and radiographically for a median of 27 months. Tumor recurrence was detected in 110 patients. For 37 patients, recurrence was heralded by clinical signs. Among the 73 asymptomatic patients who had a confirmed recurrence, disease was detected by PET/CT between 2 and 43 months, median of 6 months. Forty-five percent of observed asymptomatic recurrences were detected during the first 6 months of surveillance (95% confidence interval [CI], 34%-57%), 79% within the first 12 months (95% CI, 68%-88%), 95% within the first 24 months (95% CI, 87%-98%), and 100% within the first 48 months (95% CI, 95%-100%). CONCLUSIONS: Among HNSCC patients followed with PET/CT surveillance, 95% of observed asymptomatic recurrences were detected within 24 months after completing CRT. For patients without clinical signs of recurrence, routine PET/CT surveillance beyond the first 24 months may be of limited value and may not be cost effective.
OBJECTIVES/HYPOTHESIS: To estimate the distribution of head and neck squamous cell carcinoma (HNSCC) recurrence after definitive chemoradiation therapy (CRT) among patients who underwent 18F-fluorodeoxyglucose positron-emission tomography and computed tomography (PET/CT) surveillance. STUDY DESIGN: Retrospective review. METHODS: HNSCC patients who underwent definitive CRT from 2001 to 2008 were evaluated for recurrence with serial PET/CT. Patients were excluded if they were previously treated for recurrent disease, were treated with surgery as the primary therapeutic modality, or had inadequate clinical follow-up. Recurrence was defined by histopathologic evidence of tumor. RESULTS: Three hundred eighty-eight patients were studied. Patients in whom recurrence was not detected were followed clinically and radiographically for a median of 27 months. Tumor recurrence was detected in 110 patients. For 37 patients, recurrence was heralded by clinical signs. Among the 73 asymptomatic patients who had a confirmed recurrence, disease was detected by PET/CT between 2 and 43 months, median of 6 months. Forty-five percent of observed asymptomatic recurrences were detected during the first 6 months of surveillance (95% confidence interval [CI], 34%-57%), 79% within the first 12 months (95% CI, 68%-88%), 95% within the first 24 months (95% CI, 87%-98%), and 100% within the first 48 months (95% CI, 95%-100%). CONCLUSIONS: Among HNSCC patients followed with PET/CT surveillance, 95% of observed asymptomatic recurrences were detected within 24 months after completing CRT. For patients without clinical signs of recurrence, routine PET/CT surveillance beyond the first 24 months may be of limited value and may not be cost effective.
Authors: Amy G Rabalais; Rohan Walvekar; Daniel Nuss; Andrew McWhorter; Charles Wood; Robert Fields; Donald E Mercante; Anna M Pou Journal: Laryngoscope Date: 2009-06 Impact factor: 3.325
Authors: V A Passero; B F Branstetter; Y Shuai; D E Heron; M K Gibson; S Y Lai; S W Kim; J R Grandis; R L Ferris; J T Johnson; A Argiris Journal: Ann Oncol Date: 2010-04-29 Impact factor: 32.976
Authors: Bart M Wensing; Matthias A W Merkx; Paul F M Krabbe; Henri A M Marres; Frank J A Van den Hoogen Journal: Head Neck Date: 2010-11-29 Impact factor: 3.147
Authors: K K Ang; A Trotti; B W Brown; A S Garden; R L Foote; W H Morrison; F B Geara; D W Klotch; H Goepfert; L J Peters Journal: Int J Radiat Oncol Biol Phys Date: 2001-11-01 Impact factor: 7.038
Authors: Amy Berrington de González; Mahadevappa Mahesh; Kwang-Pyo Kim; Mythreyi Bhargavan; Rebecca Lewis; Fred Mettler; Charles Land Journal: Arch Intern Med Date: 2009-12-14
Authors: David L Schwartz; Jerry Barker; Kari Chansky; Bevan Yueh; Leila Raminfar; Pamela Drago; Christine Cha; Mary Austin-Seymour; George E Laramore; Allen D Hillel; Ernest A Weymuller; Kent E Wallner Journal: Head Neck Date: 2003-12 Impact factor: 3.147
Authors: A Gore; K Baugnon; J Beitler; N F Saba; M R Patel; X Wu; B J Boyce; A H Aiken Journal: AJNR Am J Neuroradiol Date: 2020-06-18 Impact factor: 3.825
Authors: Jon Cacicedo; Arturo Navarro; Olga Del Hoyo; Alfonso Gomez-Iturriaga; Filippo Alongi; Jose A Medina; Olgun Elicin; Andrea Skanjeti; Francesco Giammarile; Pedro Bilbao; Francisco Casquero; Berardino de Bari; Alan Dal Pra Journal: Br J Radiol Date: 2016-08-02 Impact factor: 3.039
Authors: Louise Madeleine Risør; Annika Loft; Anne Kiil Berthelsen; Frederik Cornelius Loft; Andreas Ruhvald Madsen; Ivan Richter Vogelius; Andreas Kjær; Jeppe Friborg Journal: Eur Arch Otorhinolaryngol Date: 2019-10-23 Impact factor: 2.503
Authors: Benjamin R Roman; Shivangi Lohia; Nandita Mitra; Marilene B Wang; Anna M Pou; F Christopher Holsinger; David Myssiorek; David Goldenberg; David A Asch; Judy A Shea Journal: Head Neck Date: 2020-01-10 Impact factor: 3.147
Authors: Vasavi Paidpally; Alin Chirindel; Christine H Chung; Jeremy Richmon; Wayne Koch; Harry Quon; Rathan M Subramaniam Journal: AJR Am J Roentgenol Date: 2014-08 Impact factor: 3.959